RI
CRVS icon

RTW Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

RTW Investments’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-447,607
Closed -$3.45M – 91
2025
Q4 		$3.45M Sell
447,607
-2,231,872
-83% -$17.6M 0.03% 85
2025
Q3 		$19.7M Hold
2,679,479
– – 0.24% 56
2025
Q2 		$10.7M Hold
2,679,479
– – 0.15% 60
2025
Q1 		$8.52M Hold
2,679,479
– – 0.13% 56
2024
Q4 		$14.3M Buy
+2,679,479
New +$20M 0.22% 52

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments's CRVS Position: Q1 2026 in Review

RTW Investments sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 447,607 shares — an estimated $3.45M sold.

RTW Investments first reported a position in CRVS in Q4 2024 and held it in 5 quarters. The position peaked at $19.7M in Q3 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • RTW Investments reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • RTW Investments sold 447,607 Corvus Pharmaceuticals shares in Q1 2026, an estimated $3.45M.
  • RTW Investments first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • RTW Investments's Corvus Pharmaceuticals position peaked at $19.7M in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on RTW Investments's 13F filing for Q1 2026, filed 15 May 2026.